Please assess the completion status of the following clinical trial:

Trial Title: Stem Cell Implantation in Patients Undergoing CABG

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Patients with ischemic heart disease manifested by Canadian class II or greater angina and/or New York Heart Association class II, III or IV exercise intolerance AND who have undergone diagnostic coronary angiography demonstrating at least 70% diameter narrowing of at least 2 major coronary arteries or branches or at least 50% diameter narrowing of the left main coronary artery.~* Left ventricular systolic dysfunction evaluated by echocardiography or LV angiography (LV ejection fraction less than or equal to 49%).~* No contraindications or exclusions (see below)~* Willingness to participate and ability to provide informed consent~Exclusion Criteria:~* Contraindications to magnetic resonance imaging .~* Need for emergent revascularization.~* Need for concomitant surgical procedure at the time of CABG (e.g. valve repair or replacement, aneurysm resection, etc.).~* Hemodynamically unstable patients.~* Patients with confirmed transmural myocardial infarction within 4 weeks, and/or rising cardiac biomarker proteins (i.e. troponin), and/or worsening ECG changes.~* Prior CABG surgery.~* Stroke within 1 month prior to planned CABG.~* Diagnosed with human immunodeficiency virus (HIV) or any other immune disorder or immunosuppressive medication (e.g. prednisone, cyclophosphamide, etanercept, etc.)~* Organ dysfunction~* Contra-indication for bone marrow aspiration (Thrombocytopenia \< 50.000 mm3, INR \> 2.0, use of antiplatelet agents other than aspirin).~* Hemoglobin less than 8g/dL, white blood cell count less than 4,000/mm3, absolute neutrophil count less than 1500/mm3~* Active infection~* Myelodysplastic syndrome (MDS)~* Significant cognitive impairment~* Any condition associated with a life expectancy of less than 6 months~* Patients known allergic reaction or contraindication to any of the component of the CD133+ enriched cells~* Participation in other studies concomitant with this study~* History of severe ventricular tachy-arrythmias~* Inability or unwillingness to provide written informed consent~* Positive serum pregnancy test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Autologous CD133+ Bone Marrow Stem Cells (Type: ACTIVE_COMPARATOR): Intra-myocardial injection of autologous CD133+ cells in suspension.
- Carrier Solution (Type: PLACEBO_COMPARATOR): Intra-myocardial inception of carrier solution.

Based on this trial design, predict the completion outcome and termination type (if applicable).